Company research
REGENXBIO Inc.
CIK 1590877Updated Sep 25, 2026
SecurityRGNX · NASDAQ · equity
Name history
ReGenX Biosciences, LLC · through Nov 7, 2013
RGNX price & chart
Loading TradingView…
NASDAQ:RGNX on TradingView ↗About the company
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www. REGENXBIO.com.
In the news
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm ↗
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm ↗
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX ↗
Recent filings
Entry into a Material Definitive Agreement
Items 1.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
424B5 filing
FWP filing
424B5 filing
SC TO-I/A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 453,032,000Source | 465,989,000Source | 573,970,000Source | 833,268,000Source |
| Property, Plant and Equipment, NetUSD | 104,855,000Source | 117,589,000Source | 132,103,000Source | 141,685,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 34,466,000Source | 57,526,000Source | 34,522,000Source | 96,952,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 26,379,000Source | 20,473,000Source | 24,790,000Source | 28,082,000Source |
| Assets, CurrentUSD | 281,281,000Source | 278,001,000Source | 334,971,000Source | 415,976,000Source |
| Operating Lease, Right-of-Use AssetUSD | 47,156,000Source | 53,716,000Source | 60,487,000Source | 65,116,000Source |
| Other Assets, NoncurrentUSD | 4,613,000Source | 4,000,000Source | 4,807,000Source | 6,397,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 350,299,000Source | 206,338,000Source | 262,228,000Source | 317,073,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 4,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,126,027,000Source | -932,149,000Source | -705,047,000Source | -441,553,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -687,000Source | -741,000Source | -4,429,000Source | -15,401,000Source |
| Stockholders' Equity Attributable to ParentUSD | 102,733,000Source | 259,651,000Source | 311,742,000Source | 516,195,000Source |
| Additional Paid in Capital, Common StockUSD | 1,229,442,000Source | 1,192,536,000Source | 1,021,214,000Source | 973,145,000Source |
| Liabilities and EquityUSD | 453,032,000Source | 465,989,000Source | 573,970,000Source | 833,268,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 118,095,000Source | 103,194,000Source | 130,272,000Source | 130,434,000Source |
| Operating Lease, Liability, CurrentUSD | 8,286,000Source | 7,902,000Source | 7,068,000Source | 5,997,000Source |
| Accounts Payable, CurrentUSD | 21,358,000Source | 22,798,000Source | 22,786,000Source | 27,213,000Source |
| Operating Lease, Liability, NoncurrentUSD | 65,215,000Source | 74,131,000Source | 82,222,000Source | 88,802,000Source |
| Other Liabilities, NoncurrentUSD | 638,000Source | 3,635,000Source | 6,249,000Source | 8,832,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 28,691,000Source | 20,947,000Source | 25,491,000Source | 29,586,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 240,900,000Source | 244,900,000Source | 314,100,000Source | 565,200,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -193,878,000Source | -227,102,000Source | -263,494,000Source | -280,321,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 34,563,000Source | 38,463,000Source | 40,267,000Source | 40,788,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 7,661,000Source | -9,707,000Source | -3,935,000Source | -4,822,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -123,963,000Source | -173,125,000Source | -218,407,000Source | -207,488,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -15,868,000Source | 103,446,000Source | 190,943,000Source | -11,929,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,414,000Source | 2,436,000Source | 9,960,000Source | 30,724,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 116,771,000Source | 92,683,000Source | -34,966,000Source | -28,840,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -23,060,000Source | 23,004,000Source | -62,430,000Source | -248,257,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 36,496,000Source | 59,556,000Source | 36,552,000Source | 98,982,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 285,000Source | -72,000Source | -142,000Source | 11,812,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 34,563,000Source | 38,463,000Source | 40,267,000Source | 40,788,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 240,900,000Source | 244,900,000Source | 314,100,000Source | 565,200,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -100,000Source | -900,000Source | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | -79,000Source |
| General and Administrative ExpenseUSD | 82,863,000Source | 76,619,000Source | 88,494,000Source | 85,281,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | -152,000Source | -84,000Source |
| InterestExpenseNonoperatingUSD | 45,008,000Source | 12,659,000Source | — | — |
| Investment Income, InterestUSD | 12,200,000Source | 12,100,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -193,878,000Source | -227,102,000Source | -263,494,000Source | -280,321,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -263,494,000Source | -280,321,000Source |
| Nonoperating Income (Expense)USD | -32,680,000Source | 6,244,000Source | 4,482,000Source | -17,529,000Source |
| Proceeds from Stock Options ExercisedUSD | 318,000Source | 1,512,000Source | 1,521,000Source | 2,804,000Source |
| Provision for Loan, Lease, and Other LossesUSD | — | -5,000,000Source | — | — |
| Realized Investment Gains (Losses)USD | 62,000Source | 6,616,000Source | 2,205,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 170,441,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 170,441,000Source | 83,328,000Source | 90,242,000Source | 112,724,000Source |
| Cost of RevenueUSD | — | 33,567,000Source | 37,213,000Source | 54,545,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -161,198,000Source | -233,346,000Source | -268,128,000Source | -262,876,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -193,878,000Source | -227,102,000Source | -263,646,000Source | -280,405,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | -152,000Source | -84,000Source |
| Net Income (Loss) Attributable to ParentUSD | -193,878,000Source | -227,102,000Source | -263,494,000Source | -280,321,000Source |
| Earnings Per Share, BasicUSD per share | -3.76Source | -4.59Source | -6.02Source | -6.5Source |
| Earnings Per Share, DilutedUSD per share | -3.76Source | -4.59Source | -6.02Source | -6.5Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 51,573,000Source | 49,509,000Source | 43,734,000Source | 43,152,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 51,573,000Source | 49,509,000Source | 43,734,000Source | 43,152,000Source |
| Interest Expense (non-operating)USD | 45,008,000Source | 12,659,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 331,639,000Source | 316,674,000Source | 358,370,000Source | 375,600,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | -152,000Source | -84,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 15,615,000Source | 16,215,000Source | 17,320,000Source | 12,909,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -100,000Source | -900,000Source | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | -79,000Source |
| General and Administrative ExpenseUSD | 82,863,000Source | 76,619,000Source | 88,494,000Source | 85,281,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -193,795,000Source | -227,022,000Source | -263,574,000Source | -280,341,000Source |
| Interest ExpenseUSD | — | — | 6,862,000Source | 23,254,000Source |
| Investment Income, InterestUSD | 12,200,000Source | 12,100,000Source | — | — |
| Investment Income, NetUSD | 12,245,000Source | 18,729,000Source | 11,319,000Source | 5,383,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -263,494,000Source | -280,321,000Source |
| Nonoperating Income (Expense)USD | -32,680,000Source | 6,244,000Source | 4,482,000Source | -17,529,000Source |
| Realized Investment Gains (Losses)USD | 62,000Source | 6,616,000Source | 2,205,000Source | — |
| Research and Development ExpenseUSD | 228,299,000Source | 208,522,000Source | 232,266,000Source | 242,453,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 170,441,000Source | — | — | — |
Filing attachments
rgnx-ex99_1.htm · 8-K · 2026-08-25
EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli ROCKVILLE, Md., August 25, 2026 - REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercia…
Read attachment ↗rgnx-ex99_1.htm · 8-K · 2026-08-24
EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Announces Regulatory Update on RGX-121 for MPS II ROCKVILLE, Md., August 24, 2026 - REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121 following the discovery of asymptomatic spine …
Read attachment ↗rgnx-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights • RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 • Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst o Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE® and ASCENT®, ex…
Read attachment ↗d40931dex41.htm · 8-K · 2026-07-20
EX-4.1 3 d40931dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 REGENXBIO INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: July [__], 2026 ───────────────────────────────────────────────────────────── REGENXBIO Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered ass…
Read attachment ↗d40931dex991.htm · 8-K · 2026-07-20
EX-99.1 5 d40931dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants Jul 17, 2026 at 7:00 AM EDT ROCKVILLE, Md., July 17, 2026 /PRNewswire/ - REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discount…
Read attachment ↗rgnx-ex99_1.htm · 8-K · 2026-06-29
EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 - REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NA…
Read attachment ↗